T1	Participants 602 743	postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment
T2	Participants 2702 2710	patients
T3	Participants 2501 2600	women with previously treated hormone-receptor-positive locally advanced or metastatic breast cance
